Reviewed by Michael Gill, B. Sc.
16 Tykerb Clinical Trials Near Me
Most Recent Tykerb Clinical Trials

What Are Tykerb Clinical Trials?

A wide range of Tykerb clinical trials is currently underway. Tykerb is one of two drugs used most frequently for the treatment of advanced breast cancer. These trials are interested in discovering potential uses for Tykerb in cancers in other parts of the body and at different stages of the disease process. They are also concerned with the combination of Tykerb with other treatments. The data on these trials show that experimental treatments using Tykerb range between moderate to high safety and effectiveness.

One of the most promising studies is being done to determine whether or not breast tumors will respond to a combination of Tykerb, chemotherapy, and other common anti-cancer interventions in patients diagnosed with invasive breast cancer.

Why Is Tykerb Being Studied In Clinical Trials?

Researchers are interested in Tykerb for its potential for expanded use in the treatment of cancer at different stages of the disease process, in different parts of the body, and in combination with one or more other forms of cancer treatment.

Because the side effects of Tykerb can be moderate to severe, it is usually held in reserve and only used when cancer is found to be invasive and/or advanced. However, since this drug has proven as useful as it has in treating invasive and advanced forms of breast cancer, researchers believe that its usefulness likely has the potential to render benefits to more people with a range of cancer and cancer-related conditions.

How Does Tykerb Treatment Work?

Tykerb is an anti-cancer drug that inhibits the growth and spread of cancer cells. It is used most commonly to treat a type of cancer that most often develops in the breast. More specifically, it is used when other medications have been used and failed to prevent the spread of cancer. Tykerb is prescribed for cancer patients with breast cancer that is advanced or metastatic.

The dosage depends on several factors, including:

  • The type and severity of the condition the patient is treating
  • Whether the patient has experienced any side effects from Tykerb
  • Other medical conditions
  • Other medications taken

Tykerb is taken in the form of 250 mg tablets, orally once a day. The number of tablets prescribed will depend on the above factors.

What Are Some of the Breakthrough Clinical Trials Involving Tykerb?

Herceptin and Tykerb, head-to-head Comparison, 2008

Lapatinib and Cetuximab in Patients With Solid Tumors

Drug Use Investigation for TYKERB Tablet (All Case Investigation)

FDA drug approval summary: lapatinib in combination with capecitabine for previously treated metastatic breast cancer that overexpresses HER-2

Lapatinib: a review of its use in the treatment of HER2-overexpressing, trastuzumab-refractory, advanced or metastatic breast cancer

Who Are The Key Opinion Leaders On Tykerb Clinical Trial Research?

Dr. Bella Kaufmann, director of the breast cancer unit at the cancer research center at Tel Aviv's Sheba Medical Center

James E Frampton, Division of Oncology Drug Products, Center for Drug Evaluation and Research, US Food and Drug Administration

Qin Ryan

Amna Ibrahim

About The Author

Michael Gill preview

Michael Gill - B. Sc.

First Published: October 16th, 2021

Last Reviewed: October 24th, 2022

Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.

References1 Ang KK, Harris J, Wheeler R, Weber R, Rosenthal DI, Nguyen-Tân PF, Westra WH, Chung CH, Jordan RC, Lu C, Kim H, Axelrod R, Silverman CC, Redmond KP, Gillison ML. Human papillomavirus and survival of patients with oropharyngeal cancer. N Engl J Med. 2010 Jul 1;363(1):24-35. doi: 10.1056/NEJMoa0912217. Epub 2010 Jun 7. https://pubmed.ncbi.nlm.nih.gov/205303162 Ang KK, Harris J, Wheeler R, Weber R, Rosenthal DI, Nguyen-Tân PF, Westra WH, Chung CH, Jordan RC, Lu C, Kim H, Axelrod R, Silverman CC, Redmond KP, Gillison ML. Human papillomavirus and survival of patients with oropharyngeal cancer. N Engl J Med. 2010 Jul 1;363(1):24-35. doi: 10.1056/NEJMoa0912217. Epub 2010 Jun 7. https://pubmed.ncbi.nlm.nih.gov/205303163 Adjei AA, Cohen RB, Franklin W, Morris C, Wilson D, Molina JR, Hanson LJ, Gore L, Chow L, Leong S, Maloney L, Gordon G, Simmons H, Marlow A, Litwiler K, Brown S, Poch G, Kane K, Haney J, Eckhardt SG. Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers. J Clin Oncol. 2008 May 1;26(13):2139-46. doi: 10.1200/JCO.2007.14.4956. Epub 2008 Apr 7. https://pubmed.ncbi.nlm.nih.gov/183909684 Hurria A, Gupta S, Zauderer M, Zuckerman EL, Cohen HJ, Muss H, Rodin M, Panageas KS, Holland JC, Saltz L, Kris MG, Noy A, Gomez J, Jakubowski A, Hudis C, Kornblith AB. Developing a cancer-specific geriatric assessment: a feasibility study. Cancer. 2005 Nov 1;104(9):1998-2005. https://pubmed.ncbi.nlm.nih.gov/162062525 Carey LA, Berry DA, Cirrincione CT, Barry WT, Pitcher BN, Harris LN, Ollila DW, Krop IE, Henry NL, Weckstein DJ, Anders CK, Singh B, Hoadley KA, Iglesia M, Cheang MC, Perou CM, Winer EP, Hudis CA. Molecular Heterogeneity and Response to Neoadjuvant Human Epidermal Growth Factor Receptor 2 Targeting in CALGB 40601, a Randomized Phase III Trial of Paclitaxel Plus Trastuzumab With or Without Lapatinib. J Clin Oncol. 2016 Feb 20;34(6):542-9. doi: 10.1200/JCO.2015.62.1268. Epub 2015 Nov 2. https://pubmed.ncbi.nlm.nih.gov/265277756 Blackwell KL, Burstein HJ, Storniolo AM, Rugo H, Sledge G, Koehler M, Ellis C, Casey M, Vukelja S, Bischoff J, Baselga J, O'Shaughnessy J. Randomized study of Lapatinib alone or in combination with trastuzumab in women with ErbB2-positive, trastuzumab-refractory metastatic breast cancer. J Clin Oncol. 2010 Mar 1;28(7):1124-30. doi: 10.1200/JCO.2008.21.4437. Epub 2010 Feb 1. https://pubmed.ncbi.nlm.nih.gov/201241877 Allen LF, Sebolt-Leopold J, Meyer MB. CI-1040 (PD184352), a targeted signal transduction inhibitor of MEK (MAPKK). Semin Oncol. 2003 Oct;30(5 Suppl 16):105-16. Review. https://pubmed.ncbi.nlm.nih.gov/146130318 Altomare DA, Testa JR. Perturbations of the AKT signaling pathway in human cancer. Oncogene. 2005 Nov 14;24(50):7455-64. Review. https://pubmed.ncbi.nlm.nih.gov/162882929 Robidoux A, Tang G, Rastogi P, Geyer CE Jr, Azar CA, Atkins JN, Fehrenbacher L, Bear HD, Baez-Diaz L, Sarwar S, Margolese RG, Farrar WB, Brufsky AM, Shibata HR, Bandos H, Paik S, Costantino JP, Swain SM, Mamounas EP, Wolmark N. Lapatinib as a component of neoadjuvant therapy for HER2-positive operable breast cancer (NSABP protocol B-41): an open-label, randomised phase 3 trial. Lancet Oncol. 2013 Nov;14(12):1183-92. doi: 10.1016/S1470-2045(13)70411-X. Epub 2013 Oct 4. https://pubmed.ncbi.nlm.nih.gov/2409530010 Rimawi MF, Niravath P, Wang T, Rexer BN, Forero A, Wolff AC, Nanda R, Storniolo AM, Krop I, Goetz MP, Nangia JR, Jiralerspong S, Pavlick A, Veeraraghavan J, De Angelis C, Gutierrez C, Schiff R, Hilsenbeck SG, Osborne CK; Translational Breast Cancer Research Consortium. TBCRC023: A Randomized Phase II Neoadjuvant Trial of Lapatinib Plus Trastuzumab Without Chemotherapy for 12 versus 24 Weeks in Patients with HER2-Positive Breast Cancer. Clin Cancer Res. 2020 Feb 15;26(4):821-827. doi: 10.1158/1078-0432.CCR-19-0851. Epub 2019 Oct 29. https://pubmed.ncbi.nlm.nih.gov/31662331